首页> 外文期刊>Annals of surgical oncology >Diffuse expression of RNA-binding protein IMP3 predicts high-stage lymph node metastasis and poor prognosis in colorectal adenocarcinoma.
【24h】

Diffuse expression of RNA-binding protein IMP3 predicts high-stage lymph node metastasis and poor prognosis in colorectal adenocarcinoma.

机译:RNA结合蛋白IMP3的弥漫性表达预示着结直肠腺癌的高级淋巴结转移和预后不良。

获取原文
获取原文并翻译 | 示例
           

摘要

BACKGROUND: IMP3 (insulinlike growth factor II mRNA-binding protein 3) is a newly identified oncofetal RNA-binding protein that is involved in cell growth and cell migration during the early stages of embryogenesis. This study sought to elucidate its role in tumor progression and prognosis of colorectal adenocarcinoma (CRA). METHODS: IMP3 expression in 186 surgically resected unifocal primary CRAs was analyzed by immunohistochemistry. The proportions of tumor cells positive for IMP3 were scored into diffuse (> or =50%), focal or heterogeneous (10-50%), and trace (<10%), and the expression levels were correlated with clinicopathologic features and patient survival. RESULTS: Cytoplasmic immunoreactivity for IMP3 was diffuse in 66 (35%), focal or heterogeneous in 38 (21%), and trace in 34 (18%) samples. No staining was seen in the adjacent nontumorous tissue. Diffuse IMP3 expression correlated with large tumor (>3 cm, P = .0452), high-stage tumor (IIIa-IV, P = .0417), lymph node metastasis (P = .0232), high lymph node ratio (LNR > or = .7, P = .0016), and lower 5-year survival (P = .0012). Further analysis showed that patients with high-stage CRA and diffuse IMP3 expression had the worst survival rate (P < .0001)-far worse than those without diffuse IMP3 expression (P = .0038). Moreover, multivariant analysis showed diffuse IMP3 expression, serosal invasion, LNR, tumor stage, and adjuvant chemotherapy were independent prognostic factors in CRA. CONCLUSION: Diffuse IMP3 protein expression correlates with invasion and aggressiveness during cancer growth and metastasis, and it is an important prognostic factor of CRAs.
机译:背景:IMP3(胰岛素样生长因子II mRNA结合蛋白3)是一种新鉴定的胎粪RNA结合蛋白,在胚胎发生的早期阶段参与细胞生长和细胞迁移。这项研究试图阐明其在结直肠腺癌(CRA)的肿瘤进展和预后中的作用。方法:采用免疫组织化学方法分析186例经手术切除的单灶原发性CRA的IMP3表达。将IMP3阳性的肿瘤细胞比例分为弥漫性(>或= 50%),局灶性或异质性(10-50%)和痕量(<10%),表达水平与临床病理特征和患者生存率相关。结果:IMP3的细胞质免疫反应性在66(35%)中弥散,在38(21%)中呈局灶​​性或异质性,在34(18%)样品中呈痕量。在相邻的非肿瘤组织中未见染色。弥漫性IMP3表达与大肿瘤(> 3 cm,P = .0452),晚期肿瘤(IIIa-IV,P = .0417),淋巴结转移(P = .0232),高淋巴结比率(LNR>)相关或= .7,P = .0016)和较低的5年生存率(P = .0012)。进一步的分析表明,具有高水平CRA和弥散IMP3表达的患者的生存率最差(P <.0001),远低于没有弥散IMP3表达的患者(P = .0038)。此外,多变量分析显示,CRA中弥漫性的IMP3表达,浆膜浸润,LNR,肿瘤分期和辅助化疗是独立的预后因素。结论:扩散的IMP3蛋白表达与癌症生长和转移过程中的侵袭性和侵袭性有关,是CRA的重要预后因素。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号